Greenwich LifeSciences, Inc. (GLSI) stock
Close on Nov 12, 2026Market cap $224.28MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $224.28M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 71.96
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$22.47M
- EPS, diluted
- -$1.59
- Book value per share
- $0.21
- Diluted shares
- 15M
Trading
- Previous close
- $16.09
- Open
- $15.80
- Day's range
- $14.40 – $16.08
- Volume
- 207,011
- Average volume (20 days)
- 130,920
- Index membership
- Russell 2000 (since Sep 2024)
- Beta (5 years)
- 1.54
- 52-week range
- $7.78 – $34.10
- RSI (14 days)
- 44.7
- Volatility (1 year)
- 105.9%
- Relative volume
- 1.50×
- WACC
- 12.7%
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | GLSI | S&P 500 | Difference | GLSI per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -14.0% | -2.7% | −11.3 pts | ||
| 3 months | -9.7% | -1.7% | −7.9 pts | ||
| Year to date | -27.3% | +11.9% | −39.2 pts | ||
| 1 year | +83.5% | +12.0% | +71.6 pts | ||
| 3 years | +50.2% | +78.2% | −27.9 pts | +14.5% | +21.2% |
| 5 years | -57.1% | +73.2% | −130.3 pts | -15.6% | +11.6% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Press releases
Releases Greenwich LifeSciences filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- Update
- Update
About Greenwich LifeSciences
Pharmaceutical Preparations
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies. Its lead product candidate is GLSI-100, which combines the GP2 peptide—a 9 amino acid transmembrane peptide of the HER2/neu protein—with the immunoadjuvant GM-CSF to elicit targeted immune responses and prevent breast cancer recurrences. The company evaluates this treatment specifically in HER2/neu-positive breast cancer patients who have residual disease or high-risk features following surgical resection and trastuzumab-based therapies.
Company profile, executives and historyGreenwich LifeSciences stock: common questions
What is Greenwich LifeSciences's stock price?
GLSI closed at $15.28 on Nov 12, 2026, down 5.03% on the day. Over the past 52 weeks it traded between $7.78 and $34.10.
What is Greenwich LifeSciences's market cap?
Greenwich LifeSciences was worth $224.28M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is GLSI's P/E ratio?
Greenwich LifeSciences lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.59), so it has no meaningful P/E ratio.
Does Greenwich LifeSciences pay a dividend?
No. Greenwich LifeSciences has not paid a cash dividend over the last twelve months.
How has GLSI stock performed over the past year?
Including dividends, GLSI returned +83.5% over the past year, against +12.0% for the S&P 500.
How many GLSI shares are sold short?
2M shares were sold short at the latest FINRA report, 36.94% of the float, or 12.5 days of average trading volume.
Who are Greenwich LifeSciences's competitors?
Companies most similar to Greenwich LifeSciences by business, industry and size include SLS, PYXS, ALXO, NWBO, OSTX.
See a number that looks wrong?